Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9441283 | 0.98 | HTR1A (0.54) | HTR1ADRD2HTR7HTR2CHRH1 | |
| SCHEMBL9441347 | 0.98 | HTR1A (0.54) | HTR1ADRD2HTR7HTR2CHRH1 | |
| SCHEMBL11085047 | 0.81 | HTR1A (0.39) | HTR1ADRD2HTR7HTR2CHRH1 | |
| SCHEMBL11079247 | 0.81 | HTR1A (0.39) | HTR1ADRD2HTR7HTR2CHRH1 | |
| SCHEMBL8887121 | 0.81 | HTR1A (0.55) | HTR1ADRD2HTR7HTR2CHRH1 | |
| SCHEMBL9120002 | 0.81 | HTR1A (0.55) | HTR1ADRD2HTR7HTR2CHRH1 | |
| SCHEMBL9120391 | 0.79 | HTR1A (0.54) | HTR1ADRD2HTR7HTR2CHRH1 | |
| SCHEMBL9119061 | 0.78 | HTR1A (0.53) | HTR1ADRD2HTR7HTR2CHRH1 | |
| SCHEMBL7304949 | 0.78 | HTR1A (0.52) | HTR1ADRD2HTR7HTR2CHRH1 | |
| SCHEMBL10973154 | 0.77 | FAAH (0.46) | HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | FLORIDA A&M UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| EP-0564358-B1 | 3-aminochromane spiro derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1998-11-04 | — | — | EP | disclosed |
| EP-0422134-B1 | 5-HT SELECTIVE AGENTS | ABBOTT LAB (US) | 1996-06-12 | — | — | EP | disclosed |
| US-5510374-A | USEFUL IN TREATMENT OF DISORDERS OF THE SEROTINERGIC SYSTEM | ADIR ET COMPAGNIE (FR) | 1996-04-23 | — | — | US | disclosed |
| EP-0548664-B1 | 2,3,3a-5,9b-hexahydro-1H-benzo(e)indole derivatives | HOFFMANN LA ROCHE (CH) | 1995-05-31 | — | — | EP | disclosed |
| US-5420150-A | Antidepressants and treatment of anxiety | GUILLAUMET GERALD (FR) | 1995-05-30 | — | — | US | disclosed |
| US-5397783-A | Antidepressants, anxiolytic agents | ADIR ET COMPAGNIE (FR) | 1995-03-14 | — | — | US | disclosed |
| US-5376661-A | Psychological disorders | ADIR ET COMPAGNIE (FR) | 1994-12-27 | — | — | US | disclosed |
| US-5346916-A | FOR TREATING ANIMALS SUFFERING FROM DISORDERS OF THE SEROTONINERGIC SYSTEM | ADIR ET COMPAGNIE (FR) | 1994-09-13 | — | — | US | disclosed |
| EP-0452204-B1 | 3-Aminochromane derivatives, procedure for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1994-06-15 | — | — | EP | disclosed |
| US-5049564-A | Hypotensive, 5-hydroxytryptamine | ABBOTT LABORATORIES (US) | 1991-09-17 | — | — | US | disclosed |
| WO-1991004973-A1 | INDOLE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1991-04-18 | — | — | WO | disclosed |
| EP-0422134-A1 | 5-HT SELECTIVE AGENTS. | ABBOTT LAB (US) | 1991-04-17 | — | — | EP | disclosed |
| WO-1990006927-A1 | 5-HT SELECTIVE AGENTS | ABBOTT LABORATORIES (US) | 1990-06-28 | — | — | WO | disclosed |
| US-4892879-A | 1-substituted-4-(thiazolyl-2-)-piperazines, -piperidines and tetrahydro-pyridines useful as anxioltic, psychogeriatric, antisepressant and antischiziphrenic agents | SANDOZ PHARM. CORP. (US) | 1990-01-09 | — | — | US | disclosed |
| US-4737500-A | 1-substituted-4-(thiazolyl-2-)-piperazines, -piperidines and -tetrahydropyridines useful as anxiolytic, psychogeriatric, antidepressant and antischizophrenic agents | SANDOZ PHARM. CORP. (US) | 1988-04-12 | — | — | US | disclosed |
| US-4452799-A | NEUROLEPTIC AGENTS | MEAD JOHNSON & COMPANY (US) | 1984-06-05 | — | — | US | disclosed |
| US-4423049-A | TRANQUILIZERS | MEAD JOHNSON & COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| US-4411901-A | ANTIPSYCHOTICS | MEAD JOHNSON & COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
| US-4361565-A | PSYCHOTROPIC PROPERTIES | MEAD JOHNSON & COMPANY (US) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193330-A1 | ALKYLATED TETRAHYDROISOQUINOLINES FOR BINDING TO CENTRAL NERVOUS SYSTEM RECEPTORS | NTSR2, HTR3B, NTSR1 | HTR1A 28/4885DRD2 226/4885HTR7 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.